This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gonzalez-Gomez, I. Articles by Kaartinen, V. Search for Related Content PubMed PubMed Citation Articles by Gonzalez-Gomez, I. Articles by Kaartinen, V.

(American Journal of Pathology. 1998;153:1293-1300.)
© 1998 American Society for Investigative Pathology

Animal Model

Progressive Neurodegeneration in Aspartylglycosaminuria Mice

Ignacio Gonzalez-Gomez* , Ilkka Mononen , Nora Heisterkamp* , John Groffen* and Vesa Kaartinen*

From the Section of Molecular Carcinogenesis,* Department of Pathology, Childrens Hospital Los Angeles Research Institute and University of Southern California, School of Medicine, Los Angeles, California, and Department of Clinical Chemistry, Kuopio University Hospital, Kuopio, Finland

Aspartylglycosaminuria (AGU) is one of the most common lysosomal storage disorders in humans. A mouse model for AGU has been recently generated through targeted disruption of the glycosylasparaginase gene, and at a young age the glycosyl asparaginase-deficient mice demonstrated many pathological changes found in human AGU patients (Kaartinen V, Mononen I, Voncken J-W, Gonzalez-Gomez I, Heisterkamp N, Groffen J: A mouse model for aspartylglycosaminuria. Nat Med 1996, 2:1375–1378). Our current findings demonstrate that after the age of 10 months, the general condition of null mutant mice gradually deteriorated. They suffered from a progressive motoric impairment and impaired bladder function and died prematurely. A widespread lysosomal hypertrophy in the central nervous system was detected. This neuronal vacuolation was particularly severe in the lateral thalamic nuclei, medullary reticular nuclei, vestibular nuclei, inferior olivary complex, and deep cerebellar nuclei. The oldest animals (20 months old) displayed a clear neuronal loss and gliosis, particularly in those regions, where the most severe vacuolation was found. The severe ataxic gait of the older mice was likely due to the dramatic loss of Purkinje cells, intensive astrogliosis and vacuolation of neurons in the deep cerebellar nuclei, and the severe vacuolation of the cells in vestibular and cochlear nuclei. The impaired bladder function and subsequent hydronephrosis were secondary to involvement of the central nervous system. These findings demonstrate that the glycosylasparaginase-deficient mice share many neuropathological features with human AGU patients, providing a suitable animal model to test therapeutic strategies in the treatment of the central nervous system effects in AGU.

This article has been cited by other articles:

				E. Kelo, U. Dunder, and I. Mononen Massive accumulation of Man2GlcNAc2-Asn in nonneuronal tissues of glycosylasparaginase-deficient mice and its removal by enzyme replacement therapy Glycobiology, January 1, 2005; 15(1): 79 - 85. [Abstract] [Full Text] [PDF]

				U. DUNDER, V. KAARTINEN, P. VALTONEN, E. VÄÄNÄNEN, V.-M. KOSMA, N. HEISTERKAMP, J. GROFFEN, and I. MONONEN Enzyme replacement therapy in a mouse model of aspartylglycosaminuria FASEB J, February 1, 2000; 14(2): 361 - 367. [Abstract] [Full Text]